Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 11-20 of 50 for Polycystic Kidney Disease

Edit search filters
  1. Efficacy And Safety Of Lixivaptan In The Treatment Of Autosomal Dominant Polycystic Kidney Disease

    Rochester, MN

  2. A Study To Evaluate RGLS4326 To Treat Autosomal Dominant Polycystic Kidney Disease

    Rochester, MN

  3. Efficacy And Safety Of Tolvaptan In Subjects With Chronic Kidney Disease Between Late Stage 2 To Early Stage 4 Due To Autosomal Dominant Polycystic Kidney Disease

    Rochester, MN

  4. A Study To Evaluate The Safety Of Lixivaptan In Subjects Previously Treated With Tolvaptan For Autosomal Dominant Polycystic Kidney Disease

    Rochester, MN

  5. A Study To Assess Adverse Events And Effectiveness Of IntraVenous Infusions Of ABBV-CLS-628 In Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

    Jacksonville, FL, Rochester, MN

  6. A Study Of The Long-Term Safety, Tolerability, And Effectiveness Of Tesevatinib For Patients Completing 24 Months Of Treatment For Autosomal Dominant Polycystic Kidney Disease

    Rochester, MN

  7. Evaluation Of 18F-Sodium Fluoride Positron Emission Tomography And Diffusion Magnetic Resonance Imaging To Assess Baseline Differences Between Autosomal Dominant Polycystic Kidney Disease And Healthy Subjects, And Disease Progression In Adults With ADPKD

    Rochester, MN

  8. Health and Wellness Coaching Impact in Chronic Kidney Disease Settings

    Jacksonville, FL

  9. A Study To See If Tolvaptan Is Safe In Infants And Children Who At Enrollment Are 28 Days To Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

    Rochester, MN

  10. A Study To Evaluate The Safety, Tolerability, And Effects On Blood And Urine Markers Of Single Ascending Dose Of GSK4771261 In Healthy Participants And Participants With Autosomal Dominant Polycystic Kidney Disease

    Rochester, MN

.

Mayo Clinic Footer